Article info
PDFClinical/translational cancer immunotherapy
Original research
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
- Correspondence to Dr Chuanhui Cao, Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China; huichuancao{at}163.com; Dr Jingyuan Sun, Department of Radiation Oncology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China; 15013050515{at}163.com
Citation
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
Publication history
- Accepted April 29, 2020
- First published May 26, 2020.
Online issue publication
May 26, 2020
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.